Abstract Details

Title Healthcare Cost and Utilization Before and After Diagnosis in Pediatric Patients With Newly Diagnosed Narcolepsy: A Claims-based Analysis

Topic Sleep

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 7-038

Objective To study healthcare utilization and costs in the year before and up to 2 years after narcolepsy diagnosis in children.

Background Narcolepsy, a rare neurological disorder characterized by excessive sleepiness and inability to regulate sleep-wake cycles, is associated with significant economic burden; symptom onset often occurs in childhood or adolescence.

Design/Methods This retrospective, cohort analysis of Truven MarketScan^® Commercial Claims and Encounters data identified US patients aged <18 years newly diagnosed with narcolepsy from 2012 to 2014. Annual costs, utilization, and comorbidities were compared in the year before (baseline [BL]), and year 1 (Y1) and year 2 (Y2) after diagnosis. Analyses and reporting were yearly, indexed to the narcolepsy diagnosis date.

Results 121 pediatric patients with newly diagnosed narcolepsy were continuously enrolled ≥1 year before diagnosis and ≥2 years after diagnosis. Most were 12 to 17 years old (77.7%) and 43.0% were female. Total costs did not differ between pre- and post-diagnosis years. Mean annual medical care costs per patient declined from BL ($13,144) to Y1 ($8,460) and Y2 ($5,718) post-diagnosis (nominal P<0.001 vs BL for both); drug costs increased from BL ($1,691) to Y1 ($8,556) and Y2 ($10,055) post-diagnosis (nominal P<0.001 vs BL for both). Mean annual healthcare utilization per patient was often lower after diagnosis vs BL (all nominal P<0.05): in Y2 vs BL, the number of inpatient hospitalizations was 0.02 vs 0.12, emergency department visits were 0.44 vs 0.82, physician office visits were 6.5 vs 8.5, and sleep diagnostic tests were 0.15 vs 2.12, respectively. Similar declines occurred from BL to Y1, but of a smaller magnitude.

Conclusions In pediatric patients with narcolepsy, health care utilization and costs are substantial in the year leading up to diagnosis. After diagnosis, utilization and medical costs decrease, and drug costs increase while total healthcare costs remain the same.

Authors/Disclosures
PRESENTER	No disclosure on file
Michael Broder	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Judi Profant, PhD	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��